Apogee: APG808 Phase 1 shows 55-day half-life; APG777 data support annual dosing; Phase 2 topline now mid-2025

Apogee Therapeutics, Inc.

APG808 interim Phase 1: half-life ~55 days, supports every 2-3 month dosing; well-tolerated; Phase 1b in asthma expected 1H 2025.
APG777 Phase 1 12-month data: half-life 77 days, near complete pSTAT6 inhibition, supports potential annual dosing in AD.
APG777 Phase 2 Part A 16-week topline data accelerated to mid-2025 due to strong enrollment.
Preclinical PoC for APG777+APG990 combo: Phase 1b vs DUPIXENT in AD planned for 2025, data 2H 2026.
APG333 (anti-TSLP) Phase 1 start by end 2024; combo with APG777 in asthma/COPD under planning.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.